Status:
COMPLETED
System-IGF-1 Pathway and Alzheimer's Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
URC-CIC Paris Descartes Necker Cochin
Conditions:
Alzheimer's Disease
Mild Cognitive Impairment
Eligibility:
All Genders
65+ years
Brief Summary
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and ...
Detailed Description
AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD...
Eligibility Criteria
Inclusion
- Caucasian patients after a comprehensive geriatric assessment and giving informed written consent.
- \- In each arm :
- elderly subjects with normal cognitive function,
- patients with dementia of AD type (DSM-IV and NINCDS-ADRDA criteria),
- patients with MCI (European Consortium on Alzheimer's Disease, EADC).
Exclusion
- Non AD dementia Major depression Use of anticholinesterase agent All diseases or major sensory deficits or any condition that might interfere with cognitive assessment and study objectives
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
693 Patients enrolled
Trial Details
Trial ID
NCT00647478
Start Date
October 1 2007
End Date
July 1 2012
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Broca Hospital Memory Clinic (CMRR)
Paris, Paris, France, 75013